TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

CETYLEV

ACETYLCYSTEINE
Approved 2016-01-29
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
10
Years on Market

Details

Status
Discontinued
First Approved
2016-01-29
Routes
ORAL
Dosage Forms
TABLET, EFFERVESCENT

Companies

ARBOR PHARMS LLC
Active Ingredient: ACETYLCYSTEINE

CETYLEV Approval History

Loading approval history...

What CETYLEV Treats

1 FDA approvals

Originally approved for its first indication in 2016 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CETYLEV FDA Label Details

Pro

CETYLEV Patents & Exclusivity

Latest Patent: May 2032

Patents (12 active)

US8747894 Expires May 8, 2032
US9561204 Expires May 8, 2032
US9427421 Expires May 8, 2032
+ 2 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA207916 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.